文献速递浆细胞疾病造血干细胞移植与细胞治疗

BCMA/CD19双靶向CAR-T治疗老年新诊断多发性骨髓瘤的I期研究

BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study.
PubMed 文献 · Blood Adv · 2026-01-01

该单臂I期研究评估AZD0120(原GC012F)作为≥70岁新诊断多发性骨髓瘤患者一线治疗,8例患者接受2周期VRD诱导后输注CAR-T。中位随访9.8个月,所有患者达严格完全缓解,1个月时均达MRD阴性(Euroflow 10^-6),安全性可控。

要点

  • ≥70岁NDMM患者接受2周期VRD诱导后输注AZD0120,所有患者达sCR。
  • 1个月时全部患者MRD阴性(Euroflow 10^-6),6个月可评估者100%阴性。
  • ≥3级血液毒性常见:中性粒细胞减少75%、白细胞减少50%、淋巴细胞减少25%。

核心结论

  • AZD0120在≥70岁NDMM患者中显示初步疗效和可控安全性。

研究设计与样本

  • 单臂I期研究,纳入≥70岁新诊断多发性骨髓瘤患者,接受2周期VRD诱导后输注AZD0120,剂量为1.5×10^5或3×10^5细胞/kg。
  • 共8例患者接受AZD0120,其中4例衰弱、4例非衰弱(根据IFM简化衰弱评分)。

主要发现

  • 中位随访9.8个月,≥3级治疗相关不良事件以血液毒性为主:淋巴细胞减少25%、白细胞减少50%、中性粒细胞减少75%。
  • 4例(50%)发生细胞因子释放综合征,均为1级;未观察到ICANS。
  • 所有患者达严格完全缓解,1个月时全部达MRD阴性(Euroflow 10^-6),6个月可评估者(n=7)MRD阴性率100%,12个月可评估者(n=2)100%。
  • 2例ECOG评分为2的衰弱患者输注后改善为1分。

临床怎么用

  • 对于≥70岁NDMM患者,AZD0120可作为潜在一线治疗选择,需关注血液毒性管理。

局限性

  • 单臂I期研究,样本量小(8例),随访时间短(中位9.8个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

GC012F, now renamed AZD0120, is an autologous B-cell maturation antigen and CD19 dual-targeting chimeric antigen receptor (CAR) T-cell product manufactured on the FasTCAR platform. CAR T-cell therapy has not been routinely studied in older patients with newly diagnosed multiple myeloma (NDMM), so we assessed AZD0120 as frontline treatment for patients with MM aged ≥70 years. In this single arm phase I study, patients with NDMM aged ≥70 years received 2 cycles of VRD (bortezomib/lenalidomide/dexamethasone) induction therapy followed by AZD0120 infusion at the dose of 1.5 × 105 or 3 × 105 cells per kg. Eight patients received AZD0120, with 4 frail and 4 nonfrai according to the Intergroupe Francophone du Myclome Simplified Frailty Score criteria. At a median follow-up of 9.8 months after infusion, hematologic toxicities were the most common grade ≥3 treatment-emergent adverse events, including lymphopenia (25%), leukopenia (50%), and neutropenia (75%). Four (50%) patients had cytokine release syndrome, all grade 1. No immune effector cell-associated neurotoxicity syndrome was observed. All patients achieved a stringent complete response, and all patients achieved minimal residual discase (MRD) negativity by Euroflow (10-6) at 1 month, with MRD negativity rates of 100% among evaluable patients at month 6 (n = 7) and month 12 (n = 2). Two frail patients with Eastern Cooperative Oncology Group (ECOG) performance status score of 2 improved to score 1 after infusion. AZD0120 CAR T-cell therapy shows promising preliminary efficacy and a manageable safety profile for older patients with NDMM. This trial was registered at www.clinicaltrials.gov as NCT05840107.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Liu J, Fan X, Peng L, et al. BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study. Blood Adv. 2026. PMID: 41925575. doi:10.1182/bloodadvances.2025019036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。